Synthetic Biologics Inc (SYN) 1.55 $SYN
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 42.37 (-0.37), XNPT: 8.83 (+0.06), OPXA: 0.77 (+0.05), SYN: 1.55 (+0.09), ABBV: 65.89 (+0.45), TEVA: 56.22 (-1.29), NVS: 92.25 (-0.41)
Teva Pharmaceutical Industries: Is It Time To Buy Or Sell?
Trevor Lowenthal - at Seeking Alpha - Thu Jan 01, 2:27AM CST
SYN: 1.55 (+0.09), PFE: 31.33 (+0.18), TEVA: 56.22 (-1.29)
Synthetic Biologics Commences Phase Ib Study on SYN-004 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 1:40PM CST
Synthetic Biologics, Inc. (SYN) announced the commencement and dosing of the first patient in a phase Ib study on its oral investigational candidate, SYN-004.
SYN: 1.55 (+0.09), MDCO: 26.63 (-1.04), RGDO: 0.92 (+0.01)
Synthetic Biologics Announces First Patient Dosed in Phase 1b Clinical Trial of SYN-004 for the Prevention of C. difficile Infection
PR Newswire - Tue Dec 30, 6:58AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
SYN: 1.55 (+0.09), XON: 26.11 (-1.42)
Synthetic Biologics Unveils Top-Line Safety Data on SYN-004 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 4:40PM CST
Synthetic Biologics, Inc. (SYN) announced positive results from the first safety and tolerability review in a phase Ia study on its investigational candidate, SYN-004.
SYN: 1.55 (+0.09), MDCO: 26.63 (-1.04), AMGN: 159.89 (+0.60)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 8:17AM CST
OCN: 15.03 (-0.07), SGOC: 0.74 (+0.12), NVGN: 2.16 (+0.08), EXAS: 26.79 (-0.65), TGE: 2.27 (+0.11), CZR: 15.44 (-0.25), ENTA: 50.45 (-0.40), NQ: 4.28 (+0.37), PVG: 6.16 (+0.37), RDUS: 41.21 (+2.30), CANF: 3.77 (+0.27), NG: 3.10 (+0.15), SYN: 1.55 (+0.09), GILD: 94.91 (+0.65), VSCI: 0.70 (-0.01), CNET: 1.20 (+0.05), SVM: 1.35 (+0.05)
Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection
PR Newswire - Mon Dec 22, 5:58AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1a clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
SYN: 1.55 (+0.09), XON: 26.11 (-1.42)
Acinetobacter Infections - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5pbmng/acinetobacter) has announced the addition of the "Acinetobacter Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AmpliPhi Biosciences - Melinta Therapeutics - Pfizer - Sarepta Therapeutics - Achaogen - Evolva - Novabiotics - Aridis Pharmaceuticals - FOB Synthesis - Synthetic Biologics - Trana Discovery - Cantab Biopharmaceuticals - Omnia Molecular - Northern Antibiotics - Nosopharm - Adenium Biotech - Vaxdyn For more information visit http://www.researchandmarkets.com/research/5p...netobacter
SYN: 1.55 (+0.09), SRPT: 14.94 (+0.47)
5 Under-$10 Stocks Setting Up to Trade Higher: Must-See Charts
at The Street - Mon Dec 01, 11:26AM CST
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
SYN: 1.55 (+0.09), AMRN: 1.13 (+0.15), JCP: 6.29 (-0.19), SNSS: 2.75 (+0.20), SWHC: 9.48 (+0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:46AM CST
CIMT: 8.81 (-0.05), CLRB: 3.06 (-0.03), MPX: 8.04 (-0.40), FATE: 5.14 (+0.11), TTPH: 39.72 (+0.01), PHMD: 1.47 (-0.06), BIND: 5.72 (+0.32), AXPW: 1.01 (+0.07), CANF: 3.77 (+0.27), SYN: 1.55 (+0.09), RNA: 18.83 (+0.08), CLIR: 7.24 (-0.09), VSCI: 0.70 (-0.01), OCRX: 6.29 (-0.08), GALE: 1.56 (+0.05), REI: 10.61 (+0.11), OGEN: 0.86 (-0.03), PTP: 73.41 (-0.01), FPRX: 27.71 (+0.71)
FDA OK's Synthetic Biologics' IND for C. diff therapeutic candidate
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 10:11AM CST
SYN: 1.55 (+0.09)
Premarket Gainers
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 8:12AM CST
MOLG: 3.02 (-0.03), CIMT: 8.81 (-0.05), SYN: 1.55 (+0.09), RNA: 18.83 (+0.08), GERN: 3.30 (+0.05), SRPT: 14.94 (+0.47), PTP: 73.41 (-0.01)
Synthetic Biologics Safe-to-Proceed Under IND to Initiate Clinical Trials of SYN-004 for the Prevention C. difficile Infection
PR Newswire - Mon Nov 24, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that its Investigational New Drug (IND) application which was submitted to the U.S. Food and Drug Administration (FDA) in October will be proceeding into clinical trials for the development of the Company's oral beta-lactamase enzyme SYN-004 for the prevention of Clostridium difficile (C. difficile) infection (CDI), antibiotic-associated diarrhea (AAD) and secondary infections with healthcare-acquired, drug-resistant pathogens in patients receiving intravenous (IV) beta-lactam antibiotic therapy. Synthetic Biologics plans to begin Phase 1a and 1b clinical trials shortly, with topline data expected to be reported before year-end.
SYN: 1.55 (+0.09), XON: 26.11 (-1.42)
Synthetic Biologics' (SYN) CEO Jeff Riley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 1:14PM CST
SYN: 1.55 (+0.09)
Synthetic Biologics net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 7:12AM CST
SYN: 1.55 (+0.09)
Synthetic Biologics misses by $0.03
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 5:59AM CST
SYN: 1.55 (+0.09)
Synthetic Biologics Reports Third Quarter 2014 Financial Results and Operational Highlights
PR Newswire - Fri Nov 14, 5:56AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today reported financial results for the three and nine months ended September 30, 2014, and provided an operational update.
SYN: 1.55 (+0.09)
Global Irritable Bowel Syndrome Therapeutics Pipeline Review 2014 - 28 Companies & 33 DRug Profiles
M2 - Fri Nov 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/scknzx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - Ono Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - AlbireoPharma - Lexicon Pharmaceuticals, Inc. - Yuhan Corporation - Alba Therapeutics Corporation - Ironwood Pharmaceuticals, Inc. - Rottapharm SpA - Tioga Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Drais Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Protagonist Therapeutics Inc. - Alfa Wassermann S.p.A - RaQualia Pharma Inc. - Furiex Pharmaceuticals, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - X-BODY BioSciences, Inc. - ImmusanT, Inc. - AltheRx Pharmaceuticals, Inc. - GIcare Pharma Inc - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/sc...able_bowel
SGYP: 3.20 (+0.15), FURX: 104.77 (-1.41), SYN: 1.55 (+0.09), IRWD: 15.48 (+0.16), LXRX: 0.92 (+0.01), AZN: 70.40 (+0.02), TEVA: 56.22 (-1.29)
Synthetic Biologics to Report Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 06, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that it intends to release its financial results for the three and nine months ended September 30, 2014 on Friday, November 14, 2014. The Company will hold an investor conference call on Friday, November 14th, at 8:30 a.m. EST.
SYN: 1.55 (+0.09)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 42.37 (-0.37), XNPT: 8.83 (+0.06), OPXA: 0.77 (+0.05), SYN: 1.55 (+0.09), ABBV: 65.89 (+0.45), TEVA: 56.22 (-1.29), NVS: 92.25 (-0.41)
Teva Pharmaceutical Industries: Is It Time To Buy Or Sell?
Trevor Lowenthal - at Seeking Alpha - Thu Jan 01, 2:27AM CST
SYN: 1.55 (+0.09), PFE: 31.33 (+0.18), TEVA: 56.22 (-1.29)
Synthetic Biologics Commences Phase Ib Study on SYN-004 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 1:40PM CST
Synthetic Biologics, Inc. (SYN) announced the commencement and dosing of the first patient in a phase Ib study on its oral investigational candidate, SYN-004.
SYN: 1.55 (+0.09), MDCO: 26.63 (-1.04), RGDO: 0.92 (+0.01)
Synthetic Biologics Announces First Patient Dosed in Phase 1b Clinical Trial of SYN-004 for the Prevention of C. difficile Infection
PR Newswire - Tue Dec 30, 6:58AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
SYN: 1.55 (+0.09), XON: 26.11 (-1.42)
Synthetic Biologics Unveils Top-Line Safety Data on SYN-004 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 4:40PM CST
Synthetic Biologics, Inc. (SYN) announced positive results from the first safety and tolerability review in a phase Ia study on its investigational candidate, SYN-004.
SYN: 1.55 (+0.09), MDCO: 26.63 (-1.04), AMGN: 159.89 (+0.60)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 8:17AM CST
OCN: 15.03 (-0.07), SGOC: 0.74 (+0.12), NVGN: 2.16 (+0.08), EXAS: 26.79 (-0.65), TGE: 2.27 (+0.11), CZR: 15.44 (-0.25), ENTA: 50.45 (-0.40), NQ: 4.28 (+0.37), PVG: 6.16 (+0.37), RDUS: 41.21 (+2.30), CANF: 3.77 (+0.27), NG: 3.10 (+0.15), SYN: 1.55 (+0.09), GILD: 94.91 (+0.65), VSCI: 0.70 (-0.01), CNET: 1.20 (+0.05), SVM: 1.35 (+0.05)
Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection
PR Newswire - Mon Dec 22, 5:58AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1a clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
SYN: 1.55 (+0.09), XON: 26.11 (-1.42)
Acinetobacter Infections - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5pbmng/acinetobacter) has announced the addition of the "Acinetobacter Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AmpliPhi Biosciences - Melinta Therapeutics - Pfizer - Sarepta Therapeutics - Achaogen - Evolva - Novabiotics - Aridis Pharmaceuticals - FOB Synthesis - Synthetic Biologics - Trana Discovery - Cantab Biopharmaceuticals - Omnia Molecular - Northern Antibiotics - Nosopharm - Adenium Biotech - Vaxdyn For more information visit http://www.researchandmarkets.com/research/5p...netobacter
SYN: 1.55 (+0.09), SRPT: 14.94 (+0.47)
5 Under-$10 Stocks Setting Up to Trade Higher: Must-See Charts
at The Street - Mon Dec 01, 11:26AM CST
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
SYN: 1.55 (+0.09), AMRN: 1.13 (+0.15), JCP: 6.29 (-0.19), SNSS: 2.75 (+0.20), SWHC: 9.48 (+0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:46AM CST
CIMT: 8.81 (-0.05), CLRB: 3.06 (-0.03), MPX: 8.04 (-0.40), FATE: 5.14 (+0.11), TTPH: 39.72 (+0.01), PHMD: 1.47 (-0.06), BIND: 5.72 (+0.32), AXPW: 1.01 (+0.07), CANF: 3.77 (+0.27), SYN: 1.55 (+0.09), RNA: 18.83 (+0.08), CLIR: 7.24 (-0.09), VSCI: 0.70 (-0.01), OCRX: 6.29 (-0.08), GALE: 1.56 (+0.05), REI: 10.61 (+0.11), OGEN: 0.86 (-0.03), PTP: 73.41 (-0.01), FPRX: 27.71 (+0.71)
FDA OK's Synthetic Biologics' IND for C. diff therapeutic candidate
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 10:11AM CST
SYN: 1.55 (+0.09)
Premarket Gainers
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 8:12AM CST
MOLG: 3.02 (-0.03), CIMT: 8.81 (-0.05), SYN: 1.55 (+0.09), RNA: 18.83 (+0.08), GERN: 3.30 (+0.05), SRPT: 14.94 (+0.47), PTP: 73.41 (-0.01)
Synthetic Biologics Safe-to-Proceed Under IND to Initiate Clinical Trials of SYN-004 for the Prevention C. difficile Infection
PR Newswire - Mon Nov 24, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that its Investigational New Drug (IND) application which was submitted to the U.S. Food and Drug Administration (FDA) in October will be proceeding into clinical trials for the development of the Company's oral beta-lactamase enzyme SYN-004 for the prevention of Clostridium difficile (C. difficile) infection (CDI), antibiotic-associated diarrhea (AAD) and secondary infections with healthcare-acquired, drug-resistant pathogens in patients receiving intravenous (IV) beta-lactam antibiotic therapy. Synthetic Biologics plans to begin Phase 1a and 1b clinical trials shortly, with topline data expected to be reported before year-end.
SYN: 1.55 (+0.09), XON: 26.11 (-1.42)
Synthetic Biologics' (SYN) CEO Jeff Riley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 1:14PM CST
SYN: 1.55 (+0.09)
Synthetic Biologics net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 7:12AM CST
SYN: 1.55 (+0.09)
Synthetic Biologics misses by $0.03
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 5:59AM CST
SYN: 1.55 (+0.09)
Synthetic Biologics Reports Third Quarter 2014 Financial Results and Operational Highlights
PR Newswire - Fri Nov 14, 5:56AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today reported financial results for the three and nine months ended September 30, 2014, and provided an operational update.
SYN: 1.55 (+0.09)
Global Irritable Bowel Syndrome Therapeutics Pipeline Review 2014 - 28 Companies & 33 DRug Profiles
M2 - Fri Nov 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/scknzx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - Ono Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - AlbireoPharma - Lexicon Pharmaceuticals, Inc. - Yuhan Corporation - Alba Therapeutics Corporation - Ironwood Pharmaceuticals, Inc. - Rottapharm SpA - Tioga Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Drais Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Protagonist Therapeutics Inc. - Alfa Wassermann S.p.A - RaQualia Pharma Inc. - Furiex Pharmaceuticals, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - X-BODY BioSciences, Inc. - ImmusanT, Inc. - AltheRx Pharmaceuticals, Inc. - GIcare Pharma Inc - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/sc...able_bowel
SGYP: 3.20 (+0.15), FURX: 104.77 (-1.41), SYN: 1.55 (+0.09), IRWD: 15.48 (+0.16), LXRX: 0.92 (+0.01), AZN: 70.40 (+0.02), TEVA: 56.22 (-1.29)
Synthetic Biologics to Report Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 06, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that it intends to release its financial results for the three and nine months ended September 30, 2014 on Friday, November 14, 2014. The Company will hold an investor conference call on Friday, November 14th, at 8:30 a.m. EST.
SYN: 1.55 (+0.09)
